Background and Purpose-Although intracranial thrombectomy represents the standard treatment approach for anterior circulation tandem occlusions, whether the extracranial lesion requires acute stenting remains unclear. Our aim was to investigate differences in clinical and procedural outcomes related to stenting extracranial lesions in a registry of patients undergoing thrombectomy for acute stroke.
A cute ischemic stroke in the setting of tandem extracranial carotid artery disease and intracranial large vessel occlusion is associated with poor outcomes. 1 The management of tandem lesions was variable across the randomized endovascular trials for thrombectomy in stroke with some trials excluding patients with extracranial carotid occlusions , including the SWIFT PRIME Trial (Solitaire FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke), 2 and the EXTEND IA Trial (Extending the Time for Thrombolysis in Emergency Neurological Deficits With Intra-Arterial Therapy). 3 Frequency of tandem lesions represented a significant proportion of patients in MR CLEAN (the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) 4 (32.3%), REVASCAT 5 (Revascularization With Solitaire FR Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours of Symptom Onset; 18.6%), and ESCAPE 6 (Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke; 17%). Despite the high frequency and poor prognosis of untreated tandem lesions, the best strategy for this disease remains uncertain.
Although standard practice involves revascularization of the intracranial occlusion, there is lack of consensus surrounding the best acute management of the extracranial lesion with significant variation in practice pattern. Single and multicenter studies, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] as well as clinical trial analysis, 21 have suggested that acute stenting is feasible; however, data are still lacking about optimal management, procedural considerations, and outcomes. Additionally, because stenting generally requires immediate dual antiplatelet therapy initiation, safety concerns have been raised surrounding acute stenting with some series describing high rates of intracerebral hemorrhage (ICH) 12, 22 and some authors advocating for delayed stenting as a safer alternative. 23 The STRATIS registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke; a multicenter, prospective analysis of patients presenting within 8 hours of intracranial large vessel occlusion undergoing Solitaire stent retriever thrombectomy 24 ) had no restrictions on the management of tandem lesions and allow us to study the feasibility and outcomes of different treatment paradigms.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request and with approval from the STRATIS investigators.
Study Population
A prospective, multicenter, nonrandomized, observational registry (STRATIS registry) evaluating the use of Solitaire Revascularization Device (Solitaire) and Mindframe Capture Low Profile Revascularization Device (Mindframe) in patients presenting with an acute ischemic stroke in the setting of large intracranial vessel occlusion (https://www.clinicaltrials.gov. Unique identifier: NCT02239640) was performed. Details of the registry have been previously reported. 24 In brief, 1000 eligible patients were enrolled in the registry, and 984 were included in the intent-to-treat analysis population between the time period of August 2014 and June 2016, at 55 centers in the United States. Ethics approval was received from the local institutional review board. Inclusion criteria were: confirmed symptomatic large vessel intracranial occlusion in the anterior circulation (internal carotid artery, middle cerebral artery segment M1 or M2), National Institutes of Health Stroke Scale (NIHSS) of ≥8, baseline modified Rankin Scale (mRS) of 0 to 1 and treatment within 8 hours of symptoms onset. Patients could be enrolled in the registry up to 7 days after endovascular treatment. Written informed consent was obtained from patients before enrollment. Tandem lesions were defined as cases in which an extracranial internal carotid occlusive or stenotic lesion accompanied the principal (intracranial) lesion treated. No additional specifications were made about patient selection based on baseline imaging findings, and no restrictions were placed on the management of tandem lesions.
Patient Characteristics, Imaging Features, Treatment, and Outcome Metrics
Patient characteristics analyzed included age, baseline NIHSS, baseline mRS score, history of atrial fibrillation. Imaging characteristics analyzed included baseline ASPECTS (Alberta Stroke Program Early CT Score), site of occlusion, and collateral flow graded via the ASITN scale (American Society of Intervention and Therapeutic Neuroradiology). Workflow metrics included onset to arrival at enrolling hospital, onset to arterial puncture, onset to reperfusion, and arrival to reperfusion. Additional data points considered in this analysis included: mode of presentation (direct presentation to treating center versus inter-facility transfer) and volume of patients enrolled at treating sites (with highvolume center defined as enrolling at least 30 STRATIS subjects). Treatment considerations included use of intravenous alteplase and adjunctive pharmacotherapy (eg, alteplase, abciximab, eptifibatide, tirofiban) and procedural workflow (acute stenting versus no stenting, angioplasty alone and stenting before or after thrombectomy). Details of periprocedural and postprocedural antiplatelet use were not available. Clinical outcome was defined by mRS score and mortality at 90 days postprocedure. Safety evaluations included symptomatic intracerebral hemorrhage (sICH) and parenchymal hematoma type 2.
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Statistical Analysis
Results are presented using standard descriptive statistics including the mean, SD, and median for continuous variables and frequency distributions for categorical variables. For between-group comparisons, t tests and Wilcoxon rank-sum were used for continuous variables and χ 2 tests and Fisher exact test for categorical variables. The set of independent variables considered were chosen to include relevant demographic and procedural characteristics to mitigate potential bias in the analysis. All P-values are 2-sided, with values <0.05 declared statistically significant. Statistical analyses were conducted in SAS version 9.3 (SAS Institute, Cary, NC) and R version 3.2 (R Foundation for Statistical Computing, Vienna, Austria). In addition to the base statistics package in R, the PSYCH and GMODELS libraries were used for summarization and tabulation of data.
Predictors of acute stenting and of 90-day clinical outcome were identified using multivariable logistic regression, including age, prestroke mRS, NIHSS, medical history, and occlusion location, as well as intravenous-tPA (tissue-type plasminogen activator) administration and time from stroke onset to arterial puncture. All characteristics were considered as independent variables. Modeling was performed by this method to obtain effects for each potential predictor in the presence of all others, and the adjusted effect of stenting in particular. Odds ratios and their corresponding 95% CIs were derived and presented along with significance testing.
Results
Of 984 patients included in the intention to treat analysis in the STRATIS registry, 147 (14.9%) patients presented with tandem lesions. As previously reported, 24 patients with tandem lesions versus nontandem lesions had longer median puncture-to-recanalization time (52.5 minutes versus 24 minutes; P<0.001); however, there were no differences in good functional outcome (56.2% versus 56.6%; P=1) and sICH (1.7% versus 1.4%; P=0.684). Of the tandem lesions, 80 patients underwent acute stent placement. Baseline characteristics of the no stent versus stent patients are detailed in Table 1 . Stented patients had lower incidence of atrial fibrillation and shorter onset to reperfusion therapy.
Clinical Outcomes
Both the stent and no-stent group had comparable rates of substantial reperfusion (Table 2 ). Safety end points were similar in terms of rate of parenchymal hematoma type 2 (Table 2) , sICH, and mortality. However, the stent group had significantly higher rates of good outcomes (90-day mRS, 0-2: 68.5% versus 42.2%; P=0.003). Of the 67 patients who did not undergo stent placement, 43 (64.2%) patients underwent angioplasty. The angioplasty alone subset of patients had similar substantial reperfusion, parenchymal hematoma type 2, sICH, and mortality compared with the stenting group; however, there were lower rates of good outcomes noted (Table 2) .
Multivariable analysis was performed to identify predictors of good outcomes in patients presenting with tandem lesions. As observed in prior studies of acute ischemic stroke patients undergoing endovascular therapy, low NIHSS and high ASPECTS were associated with good outcomes. When
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adjusting for baseline covariates (age, history of atrial fibrillation, baseline ASPECTS, baseline mRS, baseline NIHSS, use of intravenous-tPA, onset to arterial puncture time, treating center volume size), stenting continued to be associated with superior outcomes (Table 3) .
Procedural Characteristics of Patients Undergoing Acute Stent Placement
Of patients undergoing acute stent placement, stenting before thrombectomy versus after thrombectomy was associated with comparable rates of substantial reperfusion and good outcomes. In the no-stent group, 3% patients received *Angioplasty only is a subset of the no-stent group that underwent angioplasty alone without acute stent placement. intraarterial pharmacotherapy (IA alteplase in all cases). In the stent group, adjunctive pharmacotherapy was used in 18.8% of patients. Of patients receiving adjunctive therapies, 8 patients received intravenous eptifibatide, 3 patients received intraarterial alteplase, 3 patients received intraarterial abciximab, and 1 patient received intravenous abciximab. There was no statistical association between rate of hemorrhage (sICH and parenchymal hematoma type 2) and treatment approach. In multivariable analysis, history of atrial fibrillation was associated with lower likelihood of acute stent placement (Table 4; further procedural details are provided in Table I in the onlineonly Data Supplement).
Discussion
In this large multicenter registry of patients undergoing endovascular therapy, we find significant variation in the management of tandem lesions with 54% of patients undergoing acute stent placement. Superior outcomes were observed in patients undergoing acute stent placement with no significant difference in rates of hemorrhage or mortality.
Multiple single-center studies have demonstrated that acute stenting can be performed in the acute setting with high rates of technical success; however, variable rates of hemorrhage ranging as high as 18% to 43% 16, 20, 22 and stent thrombosis in up to 17% of cases 20 have been reported. These potential complications have led to practice variation and clinical uncertainty about the optimal approach with no studies having demonstrated superiority of acute stenting versus delayed stenting. Data from randomized controlled trials are limited. In the recently completed endovascular trials, acute stenting was performed in only a small portion of patients (REVASCAT trial 5 : 9 patients, ESCAPE trial 6 : 17 patients; MR CLEAN trial 4 : 30 patients). In the ESCAPE trial, although the number of tandem patients was small and not statistically significant, numerically there were higher rates of successful reperfusion (71% versus 46%) and good outcomes (65% versus 54%) with lower rates of death (6% versus 15%) and sICH (0% versus 8%) in the acute carotid intervention group compared with the no acute carotid intervention group. 21 Mpotsaris et al 8 similarly observed a nonsignificant trend in their small sample size towards better outcomes in the acute stenting group versus nonstenting group (54% versus 42%), as well as higher rates of independent ambulation (85% versus 63%).
The reasons for higher proportion of good outcomes in the stented group of the STRATIS registry are likely multifactorial. Given the nonrandomized nature of the treatment approach, there were some baseline differences, in particular, the acute stent group had lower NIHSS, lower rate of atrial fibrillation, and shorter onset to arterial puncture time. This may have led to provider bias as these patients may have been felt to have a smaller baseline infarct on presentation, and thus, the risk of acute stenting and subsequent hemorrhagic complication may have been perceived as lower. This superiority in the acute stent group was noted when compared with both the nostent group and the angioplasty group. Therefore, based on the results of our study, angioplasty alone may not achieve comparable outcomes compared with stenting. In multivariable analysis, acute stenting continued to be an independent predictor of good outcomes suggesting that the treatment effect persists beyond these baseline differences. Nonetheless, the small sample size of this cohort represents a limitation with regards to the validity of our results. Advantages of acute stenting are most likely related to augmentation of perfusion with a widely patent carotid artery in addition to a lower likelihood of recurrent events and reocclusion that may occur in the hyperacute setting of untreated carotid artery. 25 Because the STRATIS registry did not require verification of postprocedure carotid artery patency, this statement cannot be verified. However, previous data have suggested high rates of postprocedure reocclusion in patients awaiting emergent carotid endarterectomy (up to 16.7%). 26 It is additionally possible that the use of dual antiplatelets in the poststenting group may have played an additional role in secondary stroke prevention and recurrent events.
Once the decision is made to acutely stent, it is currently unclear whether stenting should be performed before or after thrombectomy. The approach of thrombectomy first may be preferable as it allows faster restoration of intracranial blood flow, and passage of the large bore base catheter may be sufficient to create a channel in the extracranial lesion and thus potentially negating the need for stent placement. Additionally, there are instances in which if the stent is placed before intracranial thrombectomy, the stent retriever catches on the carotid stent and potentially disrupts the device. 12, 27 However, stent first affords the advantage of potentially facilitating flow-related recanalization of the intracranial lesion, as well as stabilizing the internal carotid artery stenosis and easing passage of the base catheter across the carotid lesion. In 1 series of 77 patients undergoing acute stenting, 26% of patients who underwent stent first had partial or complete resolution of the distal intracranial occlusion; 13 however, this has not been observed to occur in all series. 18 The nature of the extracranial disease is typically atherosclerotic, although dissections can also be encountered, particularly 
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in the younger patient population. In addition, embolic occlusions of the proximal internal carotid artery have also been reported. In a recent study of 295 patients with tandem lesions, a majority (78%) of lesions were atherosclerotic in nature, and the remainder were dissections. Most patients were managed with acute stent placement regardless of cause with no differences in safety outcomes between stented and nonstented patients. 28 Even when stenting is performed, considerable uncertainty exists with regards to whether extracranial stenting should be performed before or after the intracranial thrombectomy. Prior studies have suggested that patients undergoing stent first experience a 20 minutes delay in intracranial reperfusion time 12 with 1 series reporting the carotid stenting procedure taking anywhere from 7 to 15 minutes. 27 In a single-center series of 37 patients, patients who underwent thrombectomy first had shorter angiography time (43.1 minutes versus 110.8 minutes; P<0.001) and a tendency towards better outcomes (52% versus 33.3%; P=0.319). In the STRATIS registry, we find a slightly faster but nonstatistically significant shorter puncture to reperfusion time in patients undergoing thrombectomy first but no difference in clinical outcomes between thrombectomy first and stenting first patients.
In addition to whether to stent first or thrombectomy first multiple additional questions arise about the optimal strategies to implement during acute stent placement including use of systemic heparin, intravenous antithrombotic agents (eg, intravenous glycoprotein IIb/IIIa inhibitors, intravenous aspirin), oral antithrombotics and dosing (eg, aspirin, clopidogrel, ticagrelor, tirofiban), need for pre and postangioplasty, need for embolic protection device, and choice of stent. Despite the lack of standardization, it appears that most series are associated with low rates of hemorrhage and complication, although the precise decision-making process may not have been captured. For example, in patients that have received intravenous alteplase, there may be a tendency to use less heparin or intravenous antithrombotics. Stampfl et al 18 found higher rates of ICH than other series and attribute this to higher use of tirofiban, although most of their patients also received intravenous alteplase. Similarly, Heck and Brown 22 found high rates of ICH after acute stenting which they attributed to the use of abciximab in an older patient population. Establishing and prospectively studying procedural parameters will be helpful in identifying conditions that may lead to higher complication rates.
This study has several limitations. First, enrollment in the registry was allowed up to 7 days after treatment. This introduces a potential bias in under-representing patients with poor outcomes. For example, relatives of patients experiencing early mortality may not have been approached for registry participation. This short-coming would affect both the acute stent and no-stent groups. Although certain patient characteristics were uniformly available, some data points were incomplete. For example, information on the exact antithrombotic usage (medications, dosage, timing) was not available. Additionally, the status of the carotid is unknown beyond the acute phase. The incidence of atrial fibrillation was significantly higher in nonstenting patients. Atrial fibrillation has been associated with worse clinical outcomes and higher rates of mortality, as well as worse collateral flow, lower rates of reperfusion, and higher chances of ICH. 29 However, there were still significantly better outcomes in the stented group after adjustment for baseline imbalances on multivariable analysis. Another limitation is that a selection bias may have occurred because of center-specific device selection and patient management preference (a few centers may not treat the tandem lesion acutely). Finally, the treatment of carotids and choice of antiplatelet regimen was not standardized; hence, the exact reasoning for treatment strategy remains unclear and prone to provider preference, experience, and comfort level.
Summary
In conclusion, acute stenting of extracranial carotid disease in patients presenting with tandem lesions seems to be safe. In a real-world experience, good outcomes are associated with low NIHSS, favorable ASPECTS, and acute stent placement. A prospective, randomized study with a standardized protocol is warranted to understand the best approach to this complex patient population.
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